Nivolumab in renal cell carcinoma: latest evidence and clinical potential

被引：56

作者：

Mazza, Camille ^{[2
]}

Escudier, Bernard ^{[1
]}

Albiges, Laurence

机构：

[1] Univ Paris Saclay, Gustave Roussy, Dept Med Oncol, F-94805 Villejuif, France

[2] Gustave Roussy, Dept Med Oncol, Villejuif, France

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2017年 / 9卷 / 03期

关键词：

immune checkpoint inhibitor; immunotherapy; nivolumab; programmed death-1; renal cell carcinoma; INTERFERON-ALPHA; DOUBLE-BLIND; LONG-TERM; SUNITINIB; EVEROLIMUS; SORAFENIB; PAZOPANIB; BLOCKADE; EFFICACY; SAFETY;

D O I：

10.1177/1758834016679942

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Similar to melanoma, renal cell carcinoma (RCC) has been historically considered as an immunogenic tumor, with interleukin 2 (IL-2) and interferon alpha (IFN-) being the first approved treatments in the 1990s. However, these therapies were effective in only 10-20% of cases and were not well tolerated. Recently, new insights on the interaction between the immune system and tumor have identified the programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway to be a key player in evading host immune responses. The strategy of immune checkpoint blockade is to reduce inhibitory signaling and restore the patient's natural tumor-specific T-cell-mediated immune responses. Nivolumab is the first PD-1 inhibitor to have gained approval for the treatment of patients with metastatic melanoma, squamous and nonsquamous non-small cell lung cancer (NSCLC), Hodgkin disease and recently RCC. In this review, we discuss results from studies of nivolumab in RCC, clinical experience with this agent, and its future development.

引用

页码：171 / 181

页数：11

共 50 条

[41] Definfing the therapeutic strategy in metastatic renal cell carcinoma [J].

Simonaggio, A. ;

Rivallin, P. ;

Marret, G. ;

Oudard, S. ;

Vano, Y. -A. .

ONCOLOGIE, 2018, 20 (7-12) :211-219

[42] Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma [J].

Bourlon, Maria T. ;

Gao, Dexiang ;

Trigero, Sara ;

Clemons, Julia E. ;

Breaker, Kathryn ;

Lam, Elaine T. ;

Flaig, Thomas W. .

CANCER MEDICINE, 2016, 5 (12) :3386-3393

[43] Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient With Metastatic Clear-cell Renal Cell Carcinoma [J].

Su, Harvey Yu-Li .

CLINICAL GENITOURINARY CANCER, 2018, 16 (02) :114-116

[44] Immunotherapy for Renal Cell Carcinoma [J].

Vano, Yann-Alexandre ;

Simonaggio, Audrey ;

Thibault, Constance ;

Oudard, Stephane .

BULLETIN DU CANCER, 2018, 105 :S24-S34

[45] Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States [J].

Liao, Weiting ;

Lei, Wanting ;

Feng, Mingyang ;

Yang, Yang ;

Wu, Qiuji ;

Zhou, Kexun ;

Bai, Liangliang ;

Wen, Feng ;

Li, Qiu .

ADVANCES IN THERAPY, 2021, 38 (12) :5662-5670

[46] A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma [J].

Conduit, Ciara ;

Davis, Ian D. ;

Goh, Jeffrey C. ;

Kichenadasse, Ganessan ;

Gurney, Howard ;

Harris, Carole A. ;

Pook, David ;

Krieger, Laurence ;

Parnis, Francis ;

Underhill, Craig ;

Adams, Diana ;

Roncolato, Felicia ;

Joshua, Anthony ;

Ferguson, Tom ;

Prithviraj, Prashanth ;

Morris, Michelle ;

Harrison, Michelle ;

Begbie, Stephen ;

Hovey, Elizabeth ;

George, Mathew ;

Liow, Elizabeth C. ;

Link, Emma K. ;

McJannett, Margaret ;

Gedye, Craig .

BJU INTERNATIONAL, 2024, 133 :57-67

[47] Subcutaneous versus intravenous nivolumab for renal cell carcinoma [J].

Albiges, L. ;

Bourlon, M. T. ;

Chacon, M. ;

Cutuli, H. J. ;

Chuken, Y. A. L. ;

Zurawski, B. ;

Mota, J. M. ;

Magri, I. ;

Burotto, M. ;

Luz, M. ;

de Menezes, J. ;

Ruiz, E. P. Y. ;

Fu, S. ;

Richardet, M. ;

Valderrama, B. P. ;

Maruzzo, M. ;

Bracarda, S. ;

Breckenridge, M. ;

Vezina, H. E. ;

Rathod, D. ;

Yu, Z. ;

Zhao, Y. ;

Dixon, M. ;

Perumal, D. ;

George, S. .

ANNALS OF ONCOLOGY, 2025, 36 (01) :99-107

[48] Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence [J].

Rizzo, Mimma ;

Porta, Camillo .

THERAPEUTIC ADVANCES IN UROLOGY, 2017, 9 (08) :195-207

[49] Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma [J].

Choueiri, Toni K. ;

Fishman, Mayer N. ;

Escudier, Bernard ;

McDermott, David F. ;

Drake, Charles G. ;

Kluger, Harriet ;

Stadler, Walter M. ;

Perez-Gracia, Jose Luis ;

McNeel, Douglas G. ;

Curti, Brendan ;

Harrison, Michael R. ;

Plimack, Elizabeth R. ;

Appleman, Leonard ;

Fong, Lawrence ;

Albiges, Laurence ;

Cohen, Lewis ;

Young, Tina C. ;

Chasalow, Scott D. ;

Ross-Macdonald, Petra ;

Srivastava, Shivani ;

Jure-Kunkel, Maria ;

Kurland, John F. ;

Simon, Jason S. ;

Sznol, Mario .

CLINICAL CANCER RESEARCH, 2016, 22 (22) :5461-5471

[50] An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma [J].

Zarrabi, Kevin ;

Wu, Shenhong .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (06) :695-705

← 1 2 3 4 5 →